

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib,Ivonescimab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Summit Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Revolution and Summit Collaborates to Evaluate RAS(ON) Inhibitors with Ivonescimab
Details : The collaboration aims to evaluate clinical-stage RAS(ON) inhibitors, including RMC-6236 (daraxonrasib), RMC-9805 (zoldonrasib) and RMC-6291 (elironrasib), in combination with ivonescimab.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2025
Lead Product(s) : Daraxonrasib,Ivonescimab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Summit Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Royalty Pharma
Deal Size : $1,250.0 million
Deal Type : Financing
Revolution Medicines Enters into $2 Billion Flexible Funding Agreement with Royalty Pharma
Details : The financing aims to advance the development and global commercialization of Revolution's leading RAS(ON) inhibitor portfolio, RMC-6236 (daraxonrasib), is being evaluated for RAS-mutated NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 24, 2025
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Royalty Pharma
Deal Size : $1,250.0 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines Doses First Patient in Phase 3 Trial of Daraxonrasib
Details : RMC-6236 (daraxonrasib) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven by oncogenic RAS mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)
Details : Daraxonrasib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $862.5 million
Deal Type : Public Offering
Revolution Medicines Closes $750M Offering with Full Exercise of Additional Shares
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 05, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $862.5 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $750.0 million
Deal Type : Public Offering
Revolution Medicines Prices Upsized $750M Offering of Stock & Pre-Funded Warrants
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $750.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $600.0 million
Deal Type : Public Offering
Revolution Medicines Announces Commencement of Public Offering of Common Stock
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $600.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines Doses First Patient in Phase 3 Metastatic Pancreatic Trial
Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for previously treated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RMC-6236 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines to Update RMC-6236 Pancreatic Cancer Program on July 15, 2024
Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for the treatment of pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
